(TAK) Takeda Pharmaceutical - Ratings and Ratios
Gastroenterology, Oncology, Rare Diseases, Immunology, Plasma Therapies
TAK EPS (Earnings per Share)
TAK Revenue
Description: TAK Takeda Pharmaceutical
Takeda Pharmaceutical Co Ltd (NYSE:TAK) is a Japan-based, globally active pharma company that conducts research, development, manufacturing, marketing, and out-licensing of prescription medicines across several therapeutic categories, including gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience.
The firm’s commercial portfolio features a mix of branded products such as Entyvio (IBD), Gattex/Revestive (short bowel syndrome), EOHILIA (oncology), Alofisel (Crohn’s disease), Takhzyro (hereditary angioedema), and a suite of plasma-derived biologics (e.g., Gammagard, Hyqvia). It also markets oncology agents like Velcade, Iclusig, and Adcetris, as well as CNS drugs such as Trintellix and Vyvanse/Elvanse.
Takeda maintains an extensive network of in-license, out-license, and collaborative agreements with biotech and pharma partners-including BioMarin, GlaxoSmithKline, Seagen, Denali Therapeutics, Arrowhead, and many academic institutions-allowing it to augment its pipeline and access novel modalities such as RNA-targeting and gene-editing technologies.
Key performance indicators (as of FY 2023) show revenue of approximately $31 billion, with R&D spending representing roughly 14 % of sales (~$4.5 billion), reflecting a continued emphasis on innovative biologics. The company’s pipeline contains over 30 late-stage candidates, notably in rare-disease gene therapies and next-generation oncology immunotherapies, which drive future growth expectations. An assumption here is that FY 2023 figures remain representative; any significant currency fluctuation or regulatory outcome could materially alter these metrics.
Sector-wide drivers that influence Takeda’s outlook include the aging global population (increasing demand for chronic-disease treatments), accelerating adoption of advanced therapies (cell, gene, and RNA-based), and pricing pressure from both governments and insurers. Conversely, supply-chain disruptions and heightened competition in biologics pose downside risks.
For a deeper, data-rich assessment of Takeda’s valuation and risk profile, you may find it useful to explore the company’s analytics on ValueRay, where granular financial models and scenario analyses are publicly available.
TAK Stock Overview
| Market Cap in USD | 43,582m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2008-10-27 |
TAK Stock Ratings
| Growth Rating | 39.2% |
| Fundamental | 61.6% |
| Dividend Rating | 26.7% |
| Return 12m vs S&P 500 | -11.1% |
| Analyst Rating | 4.50 of 5 |
TAK Dividends
| Dividend Yield 12m | 2.45% |
| Yield on Cost 5y | 2.50% |
| Annual Growth 5y | -2.45% |
| Payout Consistency | 91.9% |
| Payout Ratio | 0.4% |
TAK Growth Ratios
| Growth Correlation 3m | 20% |
| Growth Correlation 12m | 71.6% |
| Growth Correlation 5y | 10.3% |
| CAGR 5y | 7.51% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.32 |
| CAGR/Mean DD 3y (Pain Ratio) | 0.77 |
| Sharpe Ratio 12m | 1.57 |
| Alpha | -5.88 |
| Beta | 0.256 |
| Volatility | 19.86% |
| Current Volume | 2833.3k |
| Average Volume 20d | 2603k |
| Stop Loss | 13.4 (-3.3%) |
| Signal | 0.30 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (136.88b TTM) > 0 and > 6% of Revenue (6% = 268.81b TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 3.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.67% (prev 14.55%; Δ -6.89pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.08 (>3.0%) and CFO 1102.30b > Net Income 136.88b (YES >=105%, WARN >=100%) |
| Net Debt (4155.93b) to EBITDA (1193.98b) ratio: 3.48 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.18b) change vs 12m ago -0.06% (target <= -2.0% for YES) |
| Gross Margin 61.60% (prev 58.26%; Δ 3.34pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 29.64% (prev 27.20%; Δ 2.44pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 1.93 (EBITDA TTM 1193.98b / Interest Expense TTM 229.64b) >= 6 (WARN >= 3) |
Altman Z'' 1.05
| (A) 0.02 = (Total Current Assets 2513.12b - Total Current Liabilities 2169.59b) / Total Assets 14004.54b |
| (B) 0.08 = Retained Earnings (Balance) 1156.69b / Total Assets 14004.54b |
| (C) 0.03 = EBIT TTM 443.17b / Avg Total Assets 15116.11b |
| (D) 0.40 = Book Value of Equity 2851.40b / Total Liabilities 7138.36b |
| Total Rating: 1.05 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 61.64
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 7.98% = 3.99 |
| 3. FCF Margin 19.24% = 4.81 |
| 4. Debt/Equity 0.66 = 2.29 |
| 5. Debt/Ebitda 3.48 = -2.29 |
| 6. ROIC - WACC (= -1.83)% = -2.29 |
| 7. RoE 1.95% = 0.16 |
| 8. Rev. Trend 55.18% = 4.14 |
| 9. EPS Trend 16.61% = 0.83 |
What is the price of TAK shares?
Over the past week, the price has changed by -3.14%, over one month by -5.90%, over three months by -3.92% and over the past year by +3.19%.
Is Takeda Pharmaceutical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TAK is around 13.28 USD . This means that TAK is currently overvalued and has a potential downside of -4.18%.
Is TAK a buy, sell or hold?
- Strong Buy: 3
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the TAK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 18 | 29.7% |
| Analysts Target Price | 18 | 29.7% |
| ValueRay Target Price | 14.3 | 3.5% |
Last update: 2025-10-13 02:03
TAK Fundamental Data Overview
P/E Trailing = 48.9643
P/E Forward = 14.2653
P/S = 0.0097
P/B = 0.9832
P/EG = 0.4185
Beta = 0.256
Revenue TTM = 4480.25b JPY
EBIT TTM = 443.17b JPY
EBITDA TTM = 1193.98b JPY
Long Term Debt = 4134.80b JPY (from longTermDebt, last quarter)
Short Term Debt = 371.14b JPY (from shortTermDebt, last quarter)
Debt = 4505.94b JPY (from shortLongTermDebtTotal, last quarter)
Net Debt = 4155.93b JPY (from netDebt column, last quarter)
Enterprise Value = 10799.79b JPY (6643.86b + Debt 4505.94b - CCE 350.01b)
Interest Coverage Ratio = 1.93 (Ebit TTM 443.17b / Interest Expense TTM 229.64b)
FCF Yield = 7.98% (FCF TTM 861.91b / Enterprise Value 10799.79b)
FCF Margin = 19.24% (FCF TTM 861.91b / Revenue TTM 4480.25b)
Net Margin = 3.06% (Net Income TTM 136.88b / Revenue TTM 4480.25b)
Gross Margin = 61.60% ((Revenue TTM 4480.25b - Cost of Revenue TTM 1720.37b) / Revenue TTM)
Gross Margin QoQ = 65.24% (prev 63.73%)
Tobins Q-Ratio = 0.77 (Enterprise Value 10799.79b / Total Assets 14004.54b)
Interest Expense / Debt = 2.38% (Interest Expense 107.16b / Debt 4505.94b)
Taxrate = 17.49% (26.35b / 150.63b)
NOPAT = 365.64b (EBIT 443.17b * (1 - 17.49%))
Current Ratio = 1.16 (Total Current Assets 2513.12b / Total Current Liabilities 2169.59b)
Debt / Equity = 0.66 (Debt 4505.94b / totalStockholderEquity, last quarter 6865.26b)
Debt / EBITDA = 3.48 (Net Debt 4155.93b / EBITDA 1193.98b)
Debt / FCF = 4.82 (Net Debt 4155.93b / FCF TTM 861.91b)
Total Stockholder Equity = 7034.84b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.98% (Net Income 136.88b / Total Assets 14004.54b)
RoE = 1.95% (Net Income TTM 136.88b / Total Stockholder Equity 7034.84b)
RoCE = 3.97% (EBIT 443.17b / Capital Employed (Equity 7034.84b + L.T.Debt 4134.80b))
RoIC = 3.11% (NOPAT 365.64b / Invested Capital 11762.98b)
WACC = 4.94% (E(6643.86b)/V(11149.80b) * Re(6.96%) + D(4505.94b)/V(11149.80b) * Rd(2.38%) * (1-Tc(0.17)))
Discount Rate = 6.96% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 0.10%
[DCF Debug] Terminal Value 75.10% ; FCFE base≈688.31b ; Y1≈566.65b ; Y5≈407.42b
Fair Price DCF = 2379 (DCF Value 7513.06b / Shares Outstanding 3.16b; 5y FCF grow -21.28% → 3.0% )
EPS Correlation: 16.61 | EPS CAGR: -0.68% | SUE: -0.00 | # QB: 0
Revenue Correlation: 55.18 | Revenue CAGR: 3.67% | SUE: -0.03 | # QB: 0
Additional Sources for TAK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle